Email: cspc@cspc.cn
Media
News Center
Jan. 16
2025
SYS6043 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Jan. 13
PRUSOGLIPTIN TABLETS OBTAINS MARKETING APPROVAL GRANTED BY NMPA
Jan. 10
SYS6041 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL
Jan. 07
SYH2059 TABLETS OBTAINS CLINICAL TRIAL APPROVAL
Jan. 02
SYS6010 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA
Dec. 30
2024
LEUPRORELIN EXTENDED-RELEASE INJECTION (SYH9016) OBTAINS CLINICAL TRIAL APPROVAL
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
